Pipeline news

• Clearside Biomedical, Inc. Announces Ongoing Results in Phase 1/2 Clinical Trial in Patients with Non-infectious Uveitis

  15 October 2014

  

  Clearside Biomedical, Inc. today announced the eight-week ongoing observations in patients with non-infectious uveitis. In the phase 1/2 clinical study, eight patients diagnosed with non-infectious uveitis at three U.S. study centers received a single suprachoroidal injection of a formulation of preservative-free triamcinolone acetonide injectable suspension using Clearside’s proprietary microinjector. 

• Epic Sciences Appoints Glen Freiberg as Vice President of Regulatory Affairs and Quality Assurance

  15 September 2014

  

  Epic Sciences announced today the appointment of Glen Paul Freiberg, RAC as vice president of regulatory affairs and quality assurance. Mr. Freiberg has more than 35 years of FDA-related experience and is recognized as a key leader in successful regulatory and compliance strategies for diagnostic products. Epic’s circulating tumor cell (CTC) technology enables the rapid and minimally invasive characterization of protein biomarker and genomic profiles in CTCs allowing for superior therapy, selection and early drug resistance detection to improve the treatment of cancer.

• Clearside Biomedical, Inc. Announces Fourth Patent Allowance in the U.S. Related To Proprietary Microneedle Drug Delivery Methods and Devices

  04 September 2014

  

  Clearside Biomedical, Inc., announces the U.S. Patent and Trademark Office (USPTO) granted U.S. Patent Application No. 13/447,246 as U.S. Patent No. 8,808,225 in a patent titled, "Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle." This is the fourth patent allowance in the U.S. related to its proprietary microneedle drug delivery methods and devices.

• Clearside Biomedical, Inc. Completes $16 Million Series B Financing

  01 September 2014

  

  Clearside Biomedical, Inc., today announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund.

• New eye implant could replace glasses

  26 August 2014 Sharon Marris, Express

  

  Reading glasses may become a thing of the past as a new implant revolutionises treatment for ageing eyes.

• Marinus Pharmaceuticals, Inc. to Ring the Opening Bell of the NASDAQ Stock Market

  26 August 2014

  

  Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that in celebration of its recently completed initial public offering and NASDAQ listing it will ring the opening bell at the NASDAQ MarketSite in Times Square on Tuesday, August 26, 2014.

• Marinus Pharmaceuticals, Inc. Enters into Use Agreement with Cydex Pharmaceuticals, Inc. for Use of Captisol (R) for Ganaxolone IV

  13 August 2014

  

  Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that it has entered into an agreement with CyDex Pharmaceuticals, Inc., a wholly owned subsidiary of Ligand Pharmaceutical Incorporated, for the clinical use of Captisol, a patent protected, uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. Marinus intends to evaluate optimizing its intravenous (IV) dose form of ganaxolone with Captisol.

• Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors

  31 July 2014

  

  Epic Sciences, a private biotech company that designs and develops novel diagnostics to personalize and advance the treatment and management of cancer, announced today the appoint of Gregory T. Lucier as chairman of Epic’s board of directors. Mr. Lucier was previously chairman and CEO of Life Technologies (formerly Invitrogen). Mr. Lucier joins Epic’s board of directors to provide expertise as Epic commercializes its circulating rare cell analysis platform with special focus on the development of products and services to detect circulating tumor cells (CTCs) in cancer. 

• Entinostat Improves Treatment Outcomes When Combined with Immune Checkpoint Blockade in Preclinical Tumor Models

  31 July 2014

  

  Syndax Pharmaceuticals, Inc. today announced that newly published results demonstrate that in preclinical studies entinostat significantly improved treatment outcomes in mouse tumor models when combined with anti-PD1 and anti-CTLA4 targeted antibodies. The paper from Kim, et al. at The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, titled "Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid derived cells" was published in the journal Proceedings of the National Academy of Sciences (PNAS). 

• Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine

  30 July 2014

  

  Epic Sciences, Inc. ("Epic"), a privately held biotech company that designs and develops novel diagnostics to personalize and advance the treatment and management of cancer, announced today the completion of a $30 million Series C Preferred Stock financing. The financing included new investors RusnanoMedInvest (RMI) and Arcus Ventures, existing investors Domain Associates, Roche Venture Fund, and Pfizer Venture Investments, as well as undisclosed individual investors. With the proceeds of the financing, Epic will commercialize its circulating rare cell analysis platform with special focus on developing products and services to detect circulating tumor cells (CTC) in cancer. Epic's technology enables the rapid and minimally invasive characterization of protein biomarker and genomic profiles in CTCs allowing for superior therapy selection and the early drug resistance detection.